General Information of Drug Combination (ID: DCZO0BU)

Drug Combination Name
Pepstatin Pizotyline
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Pepstatin   DM9S1EA Pizotyline   DMV74ZH
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 28.83
Bliss Independence Score: 28.83
Loewe Additivity Score: 39.75
LHighest Single Agent (HSA) Score: 39.75

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Pepstatin
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Terminated [2]
Pepstatin Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Plasmodium Cysteine protease falcipain-2 (Malaria CPF2) TT7EASG Q9N6S8_PLAFA Inhibitor [4]
Plasmodium Plasmepsin 2 (Malaria PLA2) TTXMNHO PLM2_PLAFA Inhibitor [5]
Plasmodium Plasmepsin 1 (Malaria PLA1) TTH9VL3 PLM1_PLAFA Inhibitor [5]
Plasmodium Cysteine protease falcipain (Malaria CPF) TTJNPTK NOUNIPROTAC Inhibitor [5]
------------------------------------------------------------------------------------
Pepstatin Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cathepsin D (CTSD) OTQZ36F3 CATD_HUMAN Decreases Activity [6]
------------------------------------------------------------------------------------
Indication(s) of Pizotyline
Disease Entry ICD 11 Status REF
Headache 8A80-8A84 Approved [3]
Pizotyline Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
5-HT receptor (5HTR) TT85JO3 NOUNIPROTAC Modulator [7]
------------------------------------------------------------------------------------
Pizotyline Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
UDP-glucuronosyltransferase 2B10 (UGT2B10) DEI8NGH UDB10_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Pizotyline Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [9]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004280)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 93).
4 Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
5 Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
6 Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia HL-60 cells. Cell Death Differ. 2001 May;8(5):477-85. doi: 10.1038/sj.cdd.4400843.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
8 Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. Drug Metab Dispos. 2013 Jul;41(7):1389-97.
9 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.